Literature DB >> 35812020

Managing inoperable pancreatic cancer: the role of the pancreaticobiliary physician.

Chia Chuin Yau1, John Leeds1,2.   

Abstract

Despite our understanding of pancreatic cancer (PC), the majority of patients with this disease are incurable. Both the incidence and mortality rates for PC have increased over the last decade. At diagnosis, the majority of patients have locally advanced PC, less than 20% of patients are eligible for potentially curative resection and approximately one-third have metastatic disease. The combination of frequent advanced presentation, low resection rates and poor responses to chemotherapy make PC one of the most lethal tumours. The treatment goals are to maintain local control, manage tumour-related morbidities and improve quality of life. Patients with inoperable PC are likely to experience significant symptoms associated with their tumour, including pancreatic insufficiency, nutritional deficiencies, pain, biliary obstruction, gastric outlet obstruction and diabetes. As a result, guidance on the management of patients with inoperable PC is critical. PC is commonly referred centrally to specialist centres particularly for surgery; however, the majority do not undergo surgical intervention and thus the importance of pancreaticobiliary physicians and endoscopists. This review will focus on the non-operative management of patients with unresectable pancreatic adenocarcinoma and review some of the issues that centralisation has contributed to. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  DIABETES MELLITUS; EXOCRINE PANCREATIC FUNCTION; PANCREATIC CANCER

Year:  2022        PMID: 35812020      PMCID: PMC9234734          DOI: 10.1136/flgastro-2022-102124

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  29 in total

1.  Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.

Authors:  Miquel Porta; Xavier Fabregat; Núria Malats; Luisa Guarner; Alfredo Carrato; Ana de Miguel; Laura Ruiz; Manuel Jariod; Sergi Costafreda; Susana Coll; Juan Alguacil; Josep M Corominas; Ricard Solà; Antonio Salas; Francisco X Real
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

Review 2.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

3.  Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.

Authors:  Corinne Frere; Barbara Bournet; Sophie Gourgou; Julien Fraisse; Cindy Canivet; Jean M Connors; Louis Buscail; Dominique Farge
Journal:  Gastroenterology       Date:  2019-12-14       Impact factor: 22.682

4.  Are we meeting the standards set for endoscopy? Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice.

Authors:  Earl J Williams; Steve Taylor; Peter Fairclough; Adrian Hamlyn; Richard F Logan; Derrick Martin; Stuart A Riley; Peter Veitch; Mark Wilkinson; Paula R Williamson; Martin Lombard
Journal:  Gut       Date:  2006-12-04       Impact factor: 23.059

5.  EUS-guided choledochoduodenostomy with electrocautery-enhanced lumen-apposing metal stents in patients with malignant distal biliary obstruction: multicenter collaboration from the United Kingdom and Ireland.

Authors:  Wei On; Bharat Paranandi; Andrew M Smith; Suresh V Venkatachalapathy; Martin W James; Guruprasad P Aithal; Ioannis Varbobitis; Danny Cheriyan; Ciaran McDonald; John S Leeds; Manu K Nayar; Kofi W Oppong; Joe Geraghty; John Devlin; Wafaa Ahmed; Ryan Scott; Terence Wong; Matthew T Huggett
Journal:  Gastrointest Endosc       Date:  2021-10-09       Impact factor: 9.427

6.  EUS-guided gastroenterostomy versus duodenal stent placement and surgical gastrojejunostomy for the palliation of malignant gastric outlet obstruction: a systematic review and meta-analysis.

Authors:  Mateus Bond Boghossian; Mateus Pereira Funari; Diogo Turiani Hourneaux De Moura; Thomas R McCarty; Vitor Massaro Takamatsu Sagae; Yen-I Chen; Pastor Joaquín Ortiz Mendieta; Fernando Lopes Ponte Neto; Wanderley Marques Bernardo; Marcos Eduardo Lera Dos Santos; Filipe Tomishige Chaves; Mouen A Khashab; Eduardo Guimarães Hourneaux de Moura
Journal:  Langenbecks Arch Surg       Date:  2021-06-14       Impact factor: 3.445

7.  Antidiabetic therapies affect risk of pancreatic cancer.

Authors:  Donghui Li; Sai-Ching J Yeung; Manal M Hassan; Marina Konopleva; James L Abbruzzese
Journal:  Gastroenterology       Date:  2009-04-16       Impact factor: 22.682

Review 8.  Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer.

Authors:  Marina Kaufman; Gurpreet Singh; Sourish Das; Ronald Concha-Parra; Jonathan Erber; Carlos Micames; Frank Gress
Journal:  J Clin Gastroenterol       Date:  2010-02       Impact factor: 3.062

9.  Impact of pancreatic enzyme replacement therapy on short- and long-term outcomes in advanced pancreatic cancer: meta-analysis of randomized controlled trials.

Authors:  Khaled Ammar; John S Leeds; Chathura Bb Ratnayake; Gourab Sen; Jeremy J French; Manu Nayar; Kofi W Oppong; Benjamin Pt Loveday; Sanjay Pandanaboyana
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-15       Impact factor: 3.869

10.  The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study.

Authors:  James Rees; Jemma Mytton; Felicity Evison; Kamarjit Singh Mangat; Prashant Patel; Nigel Trudgill
Journal:  BMJ Open       Date:  2020-01-23       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.